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the effect of dapagliflozin on abrupt declines in kidney
function based on baseline subgroups. Acute kidney
injury–related serious adverse events were not significantly
different and occurred in 52 (2.5%) and 69 (3.2%)
participants in the dapagliflozin and placebo groups,
respectively (0.77 [0.54, 1.10]). Thus, in patients with CKD
and substantial albuminuria, dapagliflozin reduced the risk
of abrupt declines in kidney function.
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A cute kidney injury (AKI) occurs in approximately 13million individuals globally per year, mainly in hos-pitalized patients.1 Although more severe chronic
kidney disease (CKD) is known to be associated with elevated
AKI risk, emerging data from large epidemiologic studies
have demonstrated that episodes of AKI also increase the risk
of CKD progression.2–4 Moreover, AKI is associated with
adverse clinical outcomes, including dialysis, cardiovascular
disease, and mortality, especially in patients with diabetes and
those with significant albuminuria.4,5
Large randomized controlled trials in patients with type
2 diabetes have shown that sodium–glucose co-transporter
2 (SGLT2) inhibitors slow progression of the decline in1
c l i n i ca l t r i a l HJL Heerspink et al.: DAPA-CKD trial—dapagliflozin and AKIkidney function and reduce the risk of kidney failure.
During the early stages of development of SGLT2 inhibitors,
concerns were raised that these agents could increase the
risk of AKI resulting from hypovolemia, treatment-induced
acute reduction in glomerular filtration rate (GFR), and the
potential to trigger kidney medullary hypoxic injury. These
concerns were supported by early case reports suggesting
that risk of AKI is higher among patients with type 2
diabetes mellitus and preserved kidney function who initi-
ated SGLT2 inhibitors.6 However, large cardiovascular and
kidney outcome trials demonstrated that SGLT2 inhibitors
could in fact reduce the risk of AKI. The consistency of this
finding across multiple trials suggests that this is a class
effect and not limited to a specific SGLT2 inhibitor.
Moreover, subsequent work has identified biologically
plausible mechanisms by which SGLT2 inhibition could
reduce AKI risk.7,8
Understanding the relationship between SGLT2 inhibi-
tion and risk of AKI in patients with CKD and albuminuria
is important, as patients with CKD experience higher rates
of AKI than patients with normal or near-normal kidney
function. The Dapagliflozin and Prevention of Adverse
Outcomes in Chronic Kidney Disease (DAPA-CKD) trial
demonstrated that the SGLT2 inhibitor dapagliflozin
reduced the risk of kidney failure and heart failure hospi-
talization, and prolonged survival in patients with CKD
with and without type 2 diabetes.9 In this analysis, we
report the effect of dapagliflozin on abrupt declines in
kidney function. These events were captured in the DAPA-
CKD trial as a pre-specified exploratory outcome, defined
as the doubling of serum creatinine between 2 subsequent
visits. We also compare the frequency of serious AKI
adverse events (as reported by investigators) in patients
randomized to receive either dapagliflozin or placebo.METHODS
Study design and participants
DAPA-CKD was a randomized, double-blind, placebo-controlled,
multicenter, international trial conducted in 21 countries at 386
study sites. The study design and the primary results have been
published previously.9 Briefly, DAPA-CKD participants were $18
years of age, with an estimated GFR (eGFR) $25 and <75 ml/min
per 1.73 m2, and a urinary albumin:creatinine ratio (UACR) $200
and <5000 mg/g. Patients either with or without type 2 diabetes
were eligible for participation. Patients with type 1 diabetes, poly-
cystic kidney disease, lupus nephritis, or anti-neutrophil cytoplasmic
antibody–associated vasculitis, as well as those receiving immuno-
therapy for primary or secondary kidney disease within 6 months
prior to enrollment, were excluded. All participants were receiving
treatment with a stable dose of an angiotensin-converting enzyme
(ACE) inhibitor or angiotensin receptor blocker (ARB) for$4 weeks
prior to randomization, unless they had a documented intolerance to
these agents. The trial protocol was approved by a central or local
ethics committee at each trial site, and all participants provided
written informed consent. This study was prospectively registered on
ClinicalTrials.gov (NCT03036150) and was posted online on January
30, 2017, prior to enrollment of the first patient.2
Randomization and follow-up
Eligible participants were randomly assigned to receive either
dapagliflozin, 10 mg daily, or matching placebo. This treatment was
to be continued until the occurrence of diabetic ketoacidosis, preg-
nancy, receipt of disallowed therapy, or study completion. Following
randomization, in-person study visits were performed after 2 weeks,
at 2, 4, and 8 months, and at 4-month intervals thereafter. At each
follow-up visit, vital signs were recorded, blood and urine samples
were sent for laboratory assessment, and information on potential
study endpoints, adverse events, concomitant therapies, and study
drug adherence was collected.
Outcomes
The primary pre-specified outcome of the current analysis was an
abrupt decline in kidney function, defined as a doubling of serum
creatinine (measured by either a local or central laboratory) compared
with the most recent central laboratory serum creatinine value,
assessed in the intent-to-treat population. The doubling of serum
creatinine was adjudicated by the independent event-adjudication
committee, which was blinded to study treatment allocation. The
event adjudication committee determined whether the doubling of
serum creatinine reflected progression of the underlying CKD or was
an abrupt deterioration unrelated to the underlying disease, due rather
to another cause, such as infection, volume depletion, or cardiovas-
cular disease events. AKI reported by investigators as a serious adverse
event (SAE; i.e., an adverse event that required hospitalization, led to
prolongation of hospitalization, or was associated with death) was
assessed in the safety population. SAEs were derived from a predefined
list of kidney-related events from the preferred terms in the Medical
Dictionary for Regulatory Activities. These events were not prospec-
tively adjudicated by the event-adjudication committee. However, 2
independent reviewers who were blinded to study drug assignment
determined the most likely cause of AKI SAEs by reviewing narratives
submitted by study investigators. Any disagreement was resolved by a
third reviewer. We also evaluated all episodes of dialysis, institution of
maintenance dialysis (for at least 28 days), and mortality following a
doubling of serum creatinine or an AKI SAE. Finally, we assessed the
proportion of patients with end-stage kidney disease (ESKD) or renal
death, and all-cause mortality from the time of an abrupt decline in
kidney function event until the end of the trial.
Statistical analyses
We performed all efficacy analyses in accordance with the intention-
to-treat principle. We determined the risk of abrupt declines in
kidney function (dapagliflozin vs. placebo) by calculating the time-
to-first inter-visit doubling of serum creatinine, applying propor-
tional hazards (Cox) regression, stratified by diabetes status and
UACR (#1000 vs. >1000 mg/g). We tested for homogeneity of
treatment effects across pre-specified subgroups, defined by patient’s
demographics and laboratory measurements, by adding interaction
terms to the relevant Cox models. We assessed the validity of the
proportional hazards assumption by inspection of the log-
cumulative hazard function of each treatment group and by
including a term for the interaction between treatment assignment
and time as a time-varying covariate. We applied the Fine–Gray
modification of the Cox model to determine the subdistribution
hazard ratio (HR) of an abrupt decline in kidney function, with
death as a competing risk. Factors associated with an abrupt decline
in kidney function were collected during the trial and summarized
by treatment groups. In addition, dialysis and death outcomes afterKidney International (2021) -, -–-
Table 1 | Baseline characteristics of patients randomized to






Age, yr, mean (SD) 61.8 (12.1) 61.9 (12.1)
#65 1247 (57.9) 1239 (57.6)
>65 905 (42.1) 913 (42.4)
Sex
Male 1443 (67.1) 1436 (66.7)
Female 709 (32.9) 716 (33.3)
Race
White 1124 (52.2) 1166 (54.2)
Black or African American 104 (4.8) 87 (4)
Asian 749 (34.8) 718 (33.4)
Other 175 (8.1) 181 (8.4)
Type 2 diabetes 1455 (67.6) 1451 (67.4)
HbA1c, %, mean (SD) 7.1 (1.7) 7.0 (1.7)
Blood pressure, mm Hg, mean (SD)
Systolic 136.7 (17.5) 137.4 (17.3)
Diastolic 77.5 (10.7) 77.5 (10.3)
eGFR, ml/min per 1.73 m2, mean (SD) 43.2 (12.3) 43.0 (12.4)
$45 880 (40.9) 902 (41.9)
<45 1272 (59.1) 1250 (58.1)
Urinary albumin-to-creatinine ratio,
mg/g, median (IQR)
965 (472–1903) 934 (482–1868)
#1000 1104 (51.3) 1121 (52.1)
>1000 1048 (48.7) 1031 (47.9)
Cardiovascular disease diagnosis 813 (37.8) 797 (37.0)
Heart failure diagnosis 235 (10.9) 233 (10.8)
Diuretic use at baseline 928 (43.1) 954 (44.3)
ACEi or ARB use at baseline 2094 (97.3) 2080 (96.7)
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker;
eGFR, estimated glomerular filtration rate; IQR, interquartile range.
Values are n (%), unless otherwise indicated.
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by treatment group.
The relative hazard of ESKD or renal death, or mortality,
following an abrupt decline in kidney function, was determined in a
companion Cox model into which an indicator of the abrupt decline
in kidney function event was fitted as a time-varying covariate (with
follow-up time starting at the time of randomization). The period of
risk prior to the abrupt decline in kidney function event was
attributed to the group with no event, so that calculation of inci-
dence rates would reflect patients’ time-updated event status. The
model was adjusted for treatment assignment, age, sex, race/
ethnicity, HbA1c, eGFR, log-transformed UACR, systolic blood
pressure, hemoglobin, body mass index, and history of cardiovas-
cular disease.
In an additional analysis, we performed a causal mediation
analysis to examine whether the effect of dapagliflozin in reducing
the relative risks of ESKD or renal death, or all-cause mortality,
could be explained by the prevention of abrupt declines in kidney
function. We used study treatment as the exposure variable, and
inter-visit doubling of serum creatinine as a binary mediator. We
included age, sex, race, type 2 diabetes status, cardiovascular disease,
eGFR, UACR, systolic and diastolic blood pressure, body mass index,
and hemoglobin as additional covariates in both the outcome model
(a Cox proportional hazards model) and the mediator model (a
binary logistic regression model).10 We determined point estimates
for the natural direct effect, the natural indirect effect, and the total
effect of dapagliflozin using the estimators provided by Valeri and
VanderWeele.11 We obtained 95% confidence intervals (CIs) through
bootstrapping with 1000 bootstrap samples. Effects were calculated
for the mean level of the continuous confounders and for the mode
of the categorical confounders.
We performed all analyses with R, version 4.0.2 (R Foundation
for Statistical Computing) or Stata, version 15 (StataCorp).
RESULTS
Study design and participants
A total of 4304 participants were enrolled in the DAPA-CKD
trial, of whom 2152 were randomly assigned to receive
dapagliflozin, 10 mg once daily, and 2152 to receive placebo,
comprising the intent-to-treat population (Supplementary
Figure S1). Three patients in each group were randomized
but not treated, comprising the safety population (dapagli-
flozin, n ¼ 2149; placebo, n ¼ 2149). Mean (SD) age was 62
(12) years; 2906 of 4304 (68%) of the cohort had type 2
diabetes; mean eGFR was 43 (12) ml/min per 1.73 m2; and
median UACR was 949 (interquartile range: 477 to 1885) mg/
g. Baseline characteristics were balanced between the dapa-
gliflozin and placebo groups (Table 1).
Effects of dapagliflozin versus placebo on abrupt declines in
kidney function
During a median of 2.4 years (interquartile range, 2.0–2.7
years) of follow-up, there were 166 abrupt decline in kidney-
function events, with a median time interval between visits of
100 days (interquartile range, 48–130 days) recorded in 154
patients (Supplementary Figure S2)—63 of 2152 patients
(2.9%; event rate 1.4 [95% CI, 1.1–1.7] per 100 patient-years)
in the dapagliflozin group, and 91 of 2152 patients (4.2%;
event rate 2.0 [95% CI, 1.6–2.5] per 100 patient-years) in theKidney International (2021) -, -–-placebo group (HR, 0.68 [95% CI, 0.49–0.94; P ¼ 0.02];
incidence rate difference 0.64 [95% CI, 0.09–1.20]). Results
were similar using the Fine–Gray model, which accounted for
the competing risk of death (subdistribution HR, 0.69 [95%
CI, 0.50–0.95; P ¼ 0.02]; Figure 1). There was no heteroge-
neity in the effect of dapagliflozin, compared with placebo, on
an abrupt decline in kidney function in pre-specified sub-
groups. Notably, the effects were consistent in patients with
versus without type 2 diabetes and were remarkably similar in
patients with a baseline eGFR above versus below 45 ml/min
per 1.73 m2, and those with a UACR above versus below 1000
mg/g (Figure 2). Effects were also similar in subgroups
created post hoc, of those with baseline diuretic use and those
with presence of heart failure at baseline (Figure 2).
Patient characteristics and conditions associated with abrupt
declines in kidney function
Participants who developed abrupt declines in kidney func-
tion were more likely to be White and less likely to be Asian,
had higher systolic blood pressure, HbA1c level, and UACR,
were more likely to report a diagnosis of type 2 diabetes, have
a history of cardiovascular disease or heart failure, and have a
prescription for diuretics at baseline (Supplementary
Table S1). During follow-up, volume depletion, dehydra-
tion, and infections were the most frequently reported factors
associated with abrupt declines in kidney function (Table 2).3
Figure 1 | Shown is the cumulative incidence curve for an abrupt decline in kidney function (at least a doubling of serum creatinine
between visits separated by a median of 100 days). Presented are the Aalen–Johansen cumulative incidence estimates, taking into account
the competing risk of mortality. CI, confidence interval.
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mortality
Following an abrupt decline in kidney function, the rate of
ESKD or renal death was 48.7 per 100 patient-years,
compared with 2.7 per 100 patient-years for those who did
not experience an abrupt decline in kidney function. The risk
of death was also increased in those who experienced an
abrupt decline in kidney function (Table 3). In a multivariable
model including selected baseline variables and treatment
assignment, the strong association persisted between doubling
of serum creatinine and ESKD or renal death (HR, 13.7 [95%
CI, 9.7–19.3]) and mortality (HR, 9.3 [95% CI, 6.6–13.2];
Table 3).
Given that there were fewer doubling of serum creatinine
events in the dapagliflozin group compared to the placebo
group, and that these events were associated with ESKD and
mortality, we explored whether the beneficial effect of dapa-
gliflozin on ESKD and mortality could be explained by its
reduction in risk of abrupt declines in kidney function. In a
causal mediation analysis model, the direct effect of dapa-
gliflozin (transition from “No AKI” to “ESKD/renal death or
mortality” in Figure 3) approximated the total effects, indi-
cating that almost all of the benefit of dapagliflozin on these
clinical endpoints occurred through mechanisms distinct
from abrupt declines in kidney function (Figure 3).Effects on AKI-related SAEs
Overall, investigator-reported AKI-related SAEs occurred in
54 of 2149 participants (2.5%; event rate 1.2 per 100 patient-
years) in the dapagliflozin group, and 69 of 2149 participants
(3.2%; event rate 1.5 per 100 patient-years) in the placebo
group (HR, 0.77 [95% CI, 0.54–1.10; P ¼ 0.15]; incidence
rate difference 0.35 [95% CI, 0.14 to 0.86]). Accounting for4
the competing risk of mortality did not alter our findings; the
effect size for AKI-related SAEs using the Fine–Gray modi-
fication of the Cox model was identical (subdistribution HR,
0.77 [95% CI, 0.54–1.10; P ¼ 0.16]; Supplementary
Figure S3).
DISCUSSION
Initiation of SGLT2 inhibitors is associated12,13 with an abrupt
rise in serum creatinine and a corresponding decline in eGFR
of 3–5 ml/min per 1.73 m2. Prior to the availability of data
from cardiovascular safety trials, there was concern among
some clinicians that the abrupt rise in creatinine might be a
signal of harm related to AKI that had a deleterious effect on
survival—an effect amplified in the presence of CKD and
increased albuminuria.4,5 In this analysis from the DAPA-
CKD trial, we demonstrated that dapagliflozin, compared
with placebo, was associated with a lower risk of an abrupt
decline in kidney function. In addition, investigator-reported
AKI SAEs occurred less frequently with dapagliflozin,
compared with placebo. These data support the favorable
benefit–risk profile of dapagliflozin, and endorse the revised
clinical practice guidelines recommending the use of SGLT2
inhibitors in patients with CKD.14
Long-term safety data from other cardiovascular outcome
trials (starting with the Empagliflozin Cardiovascular
Outcome Event Trial in Type 2 Diabetes Mellitus Patients
[EMPA-REG OUTCOME] and subsequently endorsed by
other cardiovascular outcome trials) have demonstrated the
safety of SGLT2 inhibitors with respect to AKI, and in fact,
they have suggested that AKI risk is reduced with these
therapies in patients with type 2 diabetes and preserved
kidney function.15 Our observations are also consistent with
analyses in patients with type 2 diabetes and CKD from theKidney International (2021) -, -–-
Figure 2 | Forest plot shows the incidence of an abrupt decline in kidney function (at least a doubling of serum creatinine between
visits separated by a median of 100 days), by subgroups. CI, confidence interval; eGFR, estimated glomerular filtration rate; UACR, urinary
albumin-to-creatinine ratio.
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diovascular Outcomes in Patients With Diabetic Nephropathy
(CREDENCE) trial, in which the HR for AKI SAEs was 0.79
(95% CI, 0.52–1.19).15 In addition, a network meta-analysis
comparing the risk of AKI across different classes of
glucose-lowering agents showed that, compared to placebo,
SGLT2 inhibitors reduce the risk of AKI, whereas effects were
neutral for glucagon-like peptide-1 receptor agonists and
dipeptidyl peptidase-4 inhibitors.16 Important to note is that
the signal for protection against AKI risk was consistent
across a range of subgroups, indicating that dapagliflozin is
protective even in higher-risk patients, such as those with type
2 diabetes, heart failure, more severe albuminuria, or those
already using diuretics. Our results are also in keeping with
findings from analyses in the Study to Evaluate the Effect of
Dapagliflozin on the Incidence of Worsening Heart Failure or
Cardiovascular Death in Patients With Chronic Heart Failure
(DAPA-HF) trial, in which dapagliflozin reduced the risk of
AKI, defined as a doubling of serum creatinine between 2
subsequent visits, by 44%.17 Finally, this signal of kidney
safety in relation to AKI has been mirrored in “real-worldKidney International (2021) -, -–-evidence” studies involving SGLT2 inhibitors, suggesting that
safety in relation to AKI extends to patients who are taking
these medications outside of the structure and monitoring
integral to clinical trials.18–21
These findings have important clinical implications. Esti-
mates indicate that 1,626,098 people in the US meet the
DAPA-CKD trial eligibility criteria.22 When we apply the
absolute risk reduction for abrupt declines in kidney function
observed in the DAPA-CKD trial to the US population, it
would translate into the prevention of 9757 events each year.
In the context of the consistent effects of dapagliflozin in
preventing abrupt declines in kidney function across regions
and patient characteristics, it is expected that many more
events would be prevented globally if treatment with dapa-
gliflozin were implemented in clinical practice.
Our data add to an emerging body of evidence demon-
strating that acute episodes precede and predict accelerated
irreversible decline in kidney function and mortality. DAPA-
CKD trial participants who experienced abrupt declines in
kidney function experienced an approximately 14-fold higher
risk of ESKD or renal death, and a 9-fold higher risk of5
Table 2 | Factors associated with abrupt decline-in-kidney-function events
Total Dapagliflozin Placebo
Patients who had an event 154 (3.6) 63 (2.9) 91 (4.2)
Predisposing factors associated with eventa
Event adjudicated to be related to underlying disease, n 38 13 25
Event adjudicated to be unrelated to underlying disease,b n 116 50 66
Dehydration/volume depletion 21 (20.2) 9 (21.4) 12 (19.4)
Medication-associated 11 (10.6) 2 (4.8) 9 (14.5)
Trauma 1 (1.0) 0 (0.0) 1 (1.6)
Cardiovascular event 6 (5.8) 2 (4.8) 4 (6.5)
Infection/septic shock 24 (23.1) 12 (28.6) 12 (19.4)
Acute exacerbation of existing kidney disease 2 (1.9) 1 (2.4) 1 (1.6)
Other 5 (4.8) 2 (4.8) 3 (4.8)
Unknown 50 (43.1) 22 (44.0) 28 (42.4)
Event
Requiring dialysis 59 (38.3) 23 (36.5) 36 (39.6)
Requiring maintenance dialysis after AKI 32 (20.8) 13 (20.6) 19 (20.9)
Death after AKI 43 (27.9) 16 (25.9) 27 (29.7)
Recovery of kidney function: D serum creatinine at next central laboratory measurement,c %
>25 (no recovery) 55 (56.1) 23 (54.8) 32 (57.1)
0 to #25 (partial recovery) 27 (27.6) 12 (28.6) 15 (26.8)
$0 (full recovery) 16 (16.3) 7 (16.6) 9 (16.1)
AKI, acute kidney injury.
aPredisposing factors are reported for patients with available data and in whom the event was unrelated to underlying kidney disease as adjudicated by the independent
event-adjudication committee.
bFour participants in the placebo group had more than 1 predisposing factor.
cSerum creatinine data at the next central laboratory measurement were available in 98 participants.
Seven patients (2 in the dapagliflozin and 5 in the placebo group) discontinued study medication within 28 days after the abrupt decline-in-kidney-function event.
Values are n (%), unless otherwise indicated.
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in accord with those from a meta-analysis of 13 cohort studies
demonstrating that patients with AKI had a higher risk of
ESKD and mortality.2 Dedicated studies are needed to
examine the possibility that SGLT2 inhibitors could be a
viable therapeutic option to prevent AKI and subsequent
outcomes for high-risk patients, including those undergoing
major surgery, or those with infection at high risk of devel-
oping AKI.2 The Dapagliflozin in Respiratory Failure in Pa-
tients with COVID-19 (DARE-19) trial demonstrated that
dapagliflozin was well tolerated in hospitalized patients with
COVID-19 infection, and AKI events were numerically lower
in the dapagliflozin (3.4%) compared to the placebo group
(5.5%), although this difference was not statistically
significant.23
Although the mechanisms by which SGLT2 inhibitors
reduce AKI risk are not known, several possibilities exist.8
First, SGLT2 inhibitors reduce tubular ischemia by attenu-
ating energy-intensive solute reabsorption, a process akin toTable 3 | Association between an abrupt decline in kidney funct
Outcome
Without an abrupt decline
in kidney function
Events
Event rate, 95% CI
(events per 100 patient-year)
ESKD or renal death 228 2.7 (2.4–3.1)
Mortality 204 2.2 (1.9–2.6)
CI, confidence interval; ESKD, end-stage kidney disease.
The multivariable adjusted hazard ratio for the association between doubling of serum c
and subsequent ESKD or renal death was 7.0 (95% CI, 4.4–11.3) and 9.9 (95% CI, 6.8–1
6
how beta-blockers reduce myocardial ischemia by reducing
cardiac workload.24 Second, SGLT2 inhibition is associated
with a rise in hematocrit, which increases oxygen-carrying
capacity and kidney oxygenation, thereby reducing
ischemia. Renal oxygenation may be further preserved
through optimization of left ventricular filling, thereby
maintaining adequate kidney perfusion.25 Third, SGLT2 in-
hibitor use is associated with a reduction in the use of loop
diuretics, thereby avoiding circulating volume contraction and
pre-renal ischemia.26 Finally, SGLT2 inhibition may preserve
capillary architecture and parenchymal perfusion, and protect
against apoptosis and ischemia-reperfusion, thereby helping to
preserve kidney perfusion and avoid AKI.27,28
It has been suggested that the progression of kidney
function decline, in some instances, is not linear over time but
rather involves multiple AKI episodes that eventually lead to
chronic progression of disease.29 Given that dapagliflozin
reduced the incidence of abrupt declines in kidney function,
we assessed whether the benefits of dapagliflozin on ESKD orion and ESKD/renal death and mortality




Event rate, 95% CI
(events per 100 patient-year)
44 48.7 (35.4–65.4) 13.7 (9.7–19.3)
43 33.3 (24.1–44.8) 9.3 (6.6–13.2)
reatinine events that were not attributed to the underlying disease (n ¼ 116 patients)
4.3) for the association with mortality.
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Figure 3 | Shown is the mediation of effect of dapagliflozin
treatment on end-stage kidney disease (ESKD) or all-cause
mortality outcomes by abrupt declines in kidney function. The
overall effect of dapagliflozin on ESKD/renal death or all-cause
mortality can be separated into the indirect effect (a,b) and the
direct effect (c). The direct effect represents the effect of the
intervention (dapagliflozin) on these outcomes through pathways
unrelated to abrupt declines in kidney function. The indirect effect
represents the effect of dapagliflozin on these outcomes as a
consequence of its effect on abrupt declines in kidney function.
Although the total effect of dapagliflozin can be estimated using
the intent-to-treat analysis, estimation of indirect and direct effects
requires control of confounding factors that jointly influence abrupt
declines in kidney function and the outcomes of ESKD/renal death
or all-cause mortality. AKI, acute kidney injury; CI, confidence
interval.
HJL Heerspink et al.: DAPA-CKD trial—dapagliflozin and AKI c l i n i ca l t r i a lrenal death, and on mortality, could be explained through its
beneficial effect on these acute events. In the multistate
model, the direct effect of dapagliflozin on ESKD or renal
death and mortality was of the same magnitude as the total
effect on these outcomes reported previously, suggesting that
the benefit of dapagliflozin on these clinical endpoints was
largely independent of its effect on abrupt declines in kidney
function.
In this analysis, dapagliflozin reduced the risk of doubling
of serum creatinine between 2 subsequent visits. As part of
the safety analysis, serious AKI SAEs were also nominally
reduced with dapagliflozin. The consistent effects of dapa-
gliflozin on both endpoints support the robustness of our
results. This study does have limitations. First, studying AKI
in the outpatient setting, in which laboratory testing is not
uniform and is often driven by only signs, symptoms, or
random tests, may lead to underreporting and differential
reporting between groups; however, these limitations apply to
any AKI study in the ambulatory setting. Second, although we
used an objective definition of abrupt declines in kidney
function, we may have missed some events if they occurred
and were resolved within the w3-month time intervalKidney International (2021) -, -–-between visits. Third, we did not measure biomarkers of AKI
and structural tubular damage, such as kidney injury
molecular-1 or interleukin-18. Fourth, we recognize that the
DAPA-CKD trial dataset does not permit mechanistic insight
into why SGLT2 inhibitors reduce AKI risk. Future work
should include biomarkers of kidney injury to better elucidate
these potential pathways.23,30 Finally, AKI SAEs were not
adjudicated in the DAPA-CKD trial, but they are clinically
important as they required hospitalization or prolonged
hospitalization, or led to death.
In conclusion, dapagliflozin reduced the risk of an abrupt
decline in kidney function in patients with CKD with albumin-
uria, with and without type 2 diabetes. In the context of similar
observations with SGLT2 inhibitors involved in other trials and
across different levels of cardiorenal risk, dapagliflozin may be a
viable therapeutic option to prevent AKI, a possibility that needs
to be confirmed in a dedicated randomized controlled trial.APPENDIX
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